Although significant advances in hemophilia treatment have improved patient outcomes and
quality of life, one of the greatest complications in severe hemophilia A is the development of …

The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over
the last decades, and several studies on underlying immune mechanisms and risk factors for …

Haemophilia is characterized by a spontaneous bleeding tendency, affecting mainly the
synovial joints. Recurrent joint bleeds induce a cascade of inflammatory as well as …

Introduction: Nowadays, one of the most serious treatment complications in hemophilia A is
the formation of neutralizing antibodies against coagulation factor VIII (FVIII). These so …

Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled
bleeding requiring replacement therapy with recombinant proteins given preventively or on …

The main complication of replacement therapy with factor in hemophilia A (HemA) is the
formation of inhibitors (neutralizing anti–factor VIII [FVIII] antibodies) in∼ 30% of severe …

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood
coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate …

Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of
patients. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and …

The complement system is an integral component of both innate and adaptive immunity.
However, complement is also a pathogenetic factor in many diseases. The development of …

The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in haemophilia A
(HA) patients is the major complication in treatment/prevention of haemorrhages. The …